DTNBP1 (Dysbindin) gene variants: In vivo evidence for effects on hippocampal glutamate status

Current Pharmaceutical Biotechnology

Volumn 13, Issue 8, 2012, Pages 1513-1521

  Wirth, C ^a   Schubert, F ^b   Lautenschlager, M ^a   Bruh R ^b   Klar A ^a   Majic, T ^a   Lang, U E ^a   Ehrlich, A ^a   Winterer, G ^c   Sander, T ^d   Schouler Ocak, M ^a   Gallinat, J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b PHYSIKALISCH TECHNISCHE BUNDESANSTALT   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

Author keywords

DTNBP1; Dysbindin; Glutamate; H MRS; Magnetic resonance spectroscopy; NAA

Indexed keywords

DYSBINDIN; GLUTAMIC ACID; N ACETYLASPARTIC ACID;

ADULT; ANTERIOR CINGULATE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEALTH STATUS; HIPPOCAMPUS; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; NERVE CELL; NEUROTRANSMISSION; NORMAL HUMAN; PATHOLOGY; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING HABIT; SYNAPTOGENESIS;

ADULT; CARRIER PROTEINS; FEMALE; GENOTYPE; GLUTAMIC ACID; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; SYNAPTIC TRANSMISSION; YOUNG ADULT;

EID: 84862603807     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112800784952     Document Type: Article

References (85)

1. Rees, M.L.; Lien, C.F.; Gorecki, D.C. Dystrobrevins in muscle and non-muscle tissues. Neuromuscul. Disord., 2007, 17, 123-134.
2. Puls, I.; Gallinat, J. The concept of endophenotypes in psychiatric diseases meeting the expectations? Pharmacopsychiatry, 2008, 41(Suppl. 1), S37-43.
3. Straub, R.E.; Jiang, Y.; MacLean, C.J.; Ma, Y.; Webb, B.T.; Myakishev, M.V.; Harris-Kerr, C.; Wormley, B.; Sadek, H.; Kadambi, B.; Cesare, A.J.; Gibberman, A.; Wang, X.; O'Neill, F.A.; Walsh, D.; Kendler, K.S. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am. J. Hum. Genet., 2002, 71, 337-348.
4. Funke, B.; Finn, C.T.; Plocik, A.M.; Lake, S.; DeRosse, P.; Kane, J.M.; Kucherlapati, R.; Malhotra, A.K. Association of the DTNBP1 locus with schizophrenia in a U.S. population. Am. J. Hum. Genet., 2004, 75, 891-898.
5. Kirov, G.; Ivanov, D.; Williams, N.M.; Preece, A.; Nikolov, I.; Milev, R.; Koleva, S.; Dimitrova, A.; Toncheva, D.; O'Donovan, M.C.; Owen, M.J. Strong evidence for association between the dystrobrevin binding protein 1 gene (DTNBP1) and schizophrenia in 488 parent-offspring trios from Bulgaria. Biol. Psychiatry, 2004, 55, 971-975.
6. Riley, B.; Kendler, K.S. Molecular genetic studies of schizophrenia. Eur. J. Hum. Genet.; 2006, 14, 669-680.
7. Schwab, S.G.; Knapp, M.; Mondabon, S.; Hallmayer, J.; Borrmann-Hassenbach, M.; Albus, M.; Lerer, B.; Rietschel, M.; Trixler, M.; Maier, W.; Wildenauer, D.B. Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am. J. Hum. Genet., 2003, 72, 185-190.
8. Tang, J.X.; Zhou, J.; Fan, J.B.; Li, X.W.; Shi, Y.Y.; Gu, N.F.; Feng, G.Y.; Xing, Y.L.; Shi, J.G.; He, L. Family-based association study of DTNBP1 in 6p22.3 and schizophrenia. Mol. Psychiatry, 2003, 8, 717-718.
9. Van Den Bogaert, A.; Schumacher, J.; Schulze, T.G.; Otte, A.C.; Ohlraun, S.; Kovalenko, S.; Becker, T.; Freudenberg, J.; Jönsson, E.G.; Mattila-Evenden, M.; Sedvall, G.C.; Czerski, P.M.; Kapelski, P.; Hauser, J.; Maier, W.; Rietschel, M.; Propping, P.; Nöthen, M.M.; Cichon, S. The DTNBP1 (dysbindin) gene contributes to schizophrenia, depending on family history of the disease. Am. J. Hum. Genet., 2003, 73, 1438-1443.
10. Vilella, E.; Costas, J.; Sanjuan, J.; Guitart, M.; De Diego, Y.; Carracedo, A.; Martorell, L.; Valero, J.; Labad, A.; De Frutos, R.; Nájera, C.; Moltó, M.D.; Toirac, I.; Guillamat, R.; Brunet, A.; Vallès, V.; Pérez, L.; Leon, M.; de Fonseca, F.R.; Phillips, C.; Torres, M. Association of schizophrenia with DTNBP1 but not with DAO, DAOA, NRG1 and RGS4 nor their genetic interaction. J. Psychiatr. Res., 2008, 42, 278-288.
11. Burdick, K.E.; Goldberg, T.E.; Funke, B.; Bates, J.A.; Lencz, T.; Kucherlapati, R.; Malhotra, A.K. DTNBP1 genotype influences cognitive decline in schizophrenia, Schizophr. Res., 2007, 89, 169-172.
12. Donohoe, G.; Morris, D.W.; Clarke, S.; McGhee, K.A.; Schwaiger, S.; Nangle, J.M.; Garavan, H.; Robertson, I.H.; Gill, M.; Corvin, A. Variance in neurocognitive performance is associated with dysbindin- 1 in schizophrenia: a preliminary study. Neuropsychologia, 2007, 45, 454-458.
13. Fallgatter, A.J.; Herrmann, M.J.; Hohoff, C.; Ehlis, A.C.; Jarczok, T.A.; Freitag, C.M.; Deckert, J. DTNBP1 (dysbindin) gene variants modulate prefrontal brain function in healthy individuals. Neuropsychopharmacology, 2006, 31, 2002-2010.
14. Luciano, M.; Miyajima, F.; Lind, P.A.; Bates, T.C.; Horan, M.; Harris, S.E.; Wright, M.J.; Ollier, W.E.; Hayward, C.; Pendleton, N.; Gow, A.J.; Visscher, P.M.; Starr, J.M.; Deary, I.J.; Martin, N.G.; Payton, A. Variation in the dysbindin gene and normal cognitive function in three independent population samples. Genes. Brain Behav., 2009, 8, 218-227.
15. Mutsuddi, M.; Morris, D.W.; Waggoner, S.G.; Daly, M.J.; Scolnick, E.M.; Sklar, P. Analysis of high-resolution HapMap of DTNBP1 (Dysbindin) suggests no consistency between reported common variant associations and schizophrenia. Am. J. Hum. Genet., 2006. 79(5), 903-909.
16. Li, W.; Zhang, Q.; Oiso, N.; Novak, E.K.; Gautam, R.; O'Brien, E.P.; Tinsley, C.L.; Blake, D.J.; Spritz, R.A.; Copeland, N.G.; Jenkins, N.A.; Amato, D.; Roe, B.A.; Starcevic, M.; Dell'Angelica, E.C.; Elliott, R.W.; Mishra, V.; Kingsmore, S.F.; Paylor, R.E.; Swank, R.T. Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosomerelated organelles complex 1 (BLOC-1). Nat. Genet., 2003, 35, 84-89.
17. Swank, R.T.; Sweet, H.O.; Davisson, M.T.; Reddington, M.; Novak, E.K. Sandy: a new mouse model for platelet storage pool deficiency. Genet. Res., 1991, 58, 51-62.
18. Murotani, T.; Ishizuka, T.; Hattori, S.; Hashimoto, R.; Matsuzaki, S.; Yamatodani, A. High dopamine turnover in the brains of Sandy mice. Neurosci. Lett., 2007, 421, 47-51.
19. Bhardwaj, S.K.; Baharnoori, M.; Sharif-Askari, B.; Kamath, A.; Williams, S.; Srivastava, L.K.; Behavioral characterization of dysbindin- 1 deficient sandy mice. Behav. Brain Res., 2009, 197, 435-441.
20. Cox, M.M.; Tucker, A.M.; Tang, J.; Talbot, K.; Richer, D.C.; Yeh, L.; Arnold, S.E. Neurobehavioral abnormalities in the dysbindin-1 mutant, sandy, on a C57BL/6J genetic background. Genes Brain. Behav., 2009, 8(4), 390-397.
21. Hattori, S.; Murotani, T.; Matsuzaki, S.; Ishizuka, T.; Kumamoto, N.; Takeda, M.; Tohyama, M.; Yamatodani, A.; Kunugi, H.; Hashimoto, R. Behavioral abnormalities and dopamine reductions in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. Biochem. Biophys. Res. Commun., 2008, 373, 298-302.
22. Takao, K.; Toyama, K.; Nakanishi, K.; Hattori, S.; Takamura, H.; Takeda, M.; Miyakawa, T.; Hashimoto, R. Impaired long-term memory retention and working memory in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. Mol. Brain, 2008, 1, 11.
23. Talbot, K.; Cho, D.S.; Ong, W.Y.; Benson, M.A.; Han, L.Y.; Kazi, H.A.; Kamins, J.; Hahn, C.G.; Blake, D.J.; Arnold, S.E. Dysbindin-1 is a synaptic and microtubular protein that binds brain snapin. Hum. Mol. Genet., 2006, 15, 3041-3054.
24. Feng, Y.Q.; Zhou, Z.Y.; He, X.; Wang, H.; Guo, X.L.; Hao, C.J.; Guo, Y.; Zhen, X.C.; Li, W. Dysbindin deficiency in sandy mice causes reduction of snapin and displays behaviors related to schizophrenia. Schizophr. Res., 2008, 106, 218-228.
25. Chen, X.W.; Feng, Y.Q.; Hao, C.J.; Guo, X.L.; He, X.; Zhou, Z.Y.; Guo, N.; Huang, H.P.; Xiong, W.; Zheng, H.; Zuo, P.L.; Zhang, C.X.; Li, W.; Zhou, Z. DTNBP1, a schizophrenia susceptibility gene, affects kinetics of transmitter release. J. Cell. Biol., 2008, 181, 791-801.
26. Numakawa, T.; Yagasaki, Y.; Ishimoto, T.; Okada, T.; Suzuki, T.; Iwata, N.; Ozaki, N.; Taguchi, T.; Tatsumi, M.; Kamijima, K.; Straub, R.E.; Weinberger, D.R.; Kunugi, H.; Hashimoto, R. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum. Mol. Genet., 2004, 13, 2699-2708.
27. Kubota, K.; Kumamoto, N.; Matsuzaki, S.; Hashimoto, R.; Hattori, T.; Okuda, H.; Takamura, H.; Takeda, M.; Katayama, T.; Tohyama, M. Dysbindin engages in c-Jun N-terminal kinase activity and cytoskeletal organization. Biochem. Biophys. Res. Commun., 2009, 379, 191-195.
28. Schubert, F.; Gallinat, J.; Seifert, F.; Rinneberg, H. Glutamate concentrations in human brain using single voxel proton magnetic resonance spectroscopy at 3 Tesla. Neuroimage, 2004a, 21, 1762-1771.
29. Gallinat, J.; Kunz, D.; Senkowski, D.; Kienast, T.; Seifert, F.; Schubert, F.; Heinz, A. Hippocampal glutamate concentration predicts cerebral theta oscillations during cognitive processing. Psychopharmacology (Berl.), 2006, 187, 103-111.
30. Gallinat, J.; Kunz, D.; Lang, U.E.; Neu, P.; Kassim, N.; Kienast, T.; Seifert, F.; Schubert, F.; Bajbouj, M. Association between cerebral glutamate and human behaviour: the sensation seeking personality trait. Neuroimage, 2007a, 34, 671-678
31. Montag, C.; Schubert, F.; Heinz, A.; Gallinat, J. Prefrontal cortex glutamate correlates with mental perspective-taking. PLoS ONE, 2008, 3, e3890.
32. Schubert, F.; Lahnor, B.; Seifert, F.; Rinneberg, H. Effective transverse relaxation time of the C4 proton multiplet resonance of glutamate in tissue phantoms and human brain at 3 T. Proc. Int. Soc. Magn. Reson. Med., 2004b, 11, 1491.
33. Lu, Z.H.; Chakraborty, G.; Ledeen, R.W.; Yahya, D.; Wu, G. NAcetylaspartate synthase is bimodally expressed in microsomes and mitochondria of brain. Brain Res. Mol. Brain Res., 2004, 122, 71-78.
34. Jung, R.E.; Brooks, W.M.; Yeo, R.A.; Chiulli, S.J.; Weers, D.C.; Sibbitt, W.L., Jr. Biochemical markers of intelligence: a proton MR spectroscopy study of normal human brain. Proc. Biol. Sci., 1999a, 266, 1375-1379.
35. Jung, R.E.; Yeo, R.A.; Chiulli, S.J.; Sibbitt, W.L. Jr.; Weers, D.C.; Hart, B.L.; Brooks, W.M. Biochemical markers of cognition: a proton MR spectroscopy study of normal human brain. Neuroreport, 1999b, 10, 3327-3331.
36. Valenzuela, M.J.; Sachdev, P.S.; Wen, W.; Shnier, R.; Brodaty, H.; Gillies, D. Dual voxel proton magnetic resonance spectroscopy in the healthy elderly: subcortical-frontal axonal N-acetylaspartate levels are correlated with fluid cognitive abilities independent of structural brain changes. Neuroimage, 2000, 12, 747-756.
37. Gallinat, J.; Lang, U.E.; Jacobsen, L.K.; Bajbouj, M.; Kalus, P.; von Haebler, D.; Seifert, F.; Schubert, F. Abnormal hippocampal neurochemistry in smokers: evidence from proton magnetic resonance spectroscopy at 3 T. J. Clin. Psychopharmacol., 2007b, 27, 80-84.
38. Bertolino, A.; Frye, M.; Callicott, J.H.; Mattay, V.S.; Rakow, R.; Shelton-Repella, J.; Post, R.; Weinberger, D.R. Neuronal pathology in the hippocampal area of patients with bipolar disorder: a study with proton magnetic resonance spectroscopic imaging. Biol. Psychiatry, 2003, 53, 906-913.
39. Blasi, G.; Bertolino, A.; Brudaglio, F.; Sciota, D.; Altamura, M.; Antonucci, N.; Scarabino, T.; Weinberger, D.R.; Nardini, M. Hippocampal neurochemical pathology in patients at first episode of affective psychosis: a proton magnetic resonance spectroscopic imaging study. Psychiatry Res., 2004, 131, 95-105.
40. Klar, A.A.; Ballmaier, M.; Leopold, K.; Häke, I.; Schaefer, M.; Brühl, R.; Schubert, F.; Gallinat, J. Interaction of hippocampal volume and N-acetylaspartate concentration deficits in schizophrenia: a combined MRI and 1H-MRS study. Neuroimage, 2010, 53, 51-57.
41. Molina, V.; Sanchez, J.; Reig, S.; Sanz, J.; Benito, C.; Santamarta, C.; Pascau, J.; Sarramea, F.; Gispert, J.D.; Misiego, J.M.; Palomo, T.; Desco, M. N-acetyl-aspartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease duration. Schizophr. Res., 2005, 73, 209-219.
42. Atmaca, M.; Yildirim, H.; Ozdemir, H.; Poyraz, A.K.; Tezcan, E.; Ogur, E. Hippocampal 1H MRS in first-episode bipolar I patients. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2006, 30, 1235-1239.
43. Cecil, K.M.; DelBello, M.P.; Morey, R.; Strakowski, S.M. Frontal lobe differences in bipolar disorder as determined by proton MR spectroscopy. Bipolar. Disord., 2002, 4, 357-365.
44. Marenco, S.; Bertolino, A.; Weinberger, D.R. In vivo NMR measures of NAA and the neurobiology of schizophrenia. Adv. Exp. Med. Biol., 2006, 576, 227-240; discussion 361-363
45. Winsberg, ME; Sachs, N; Tate, DL; Adalsteinsson, E; Spielman, D; Ketter, TA. Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder. Biol. Psychiatry, 2000, 47, 475-481.
46. Zuo, L.; Luo, X.; Krystal, J.H.; Cramer, J.; Charney, D.S.; Gelernter, J. The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. Pharmacogenet. Genomics, 2009, 19(6), 437-446.
47. Weickert, C.S.; Straub, R.E.; McClintock, B.W.; Matsumoto, M.; Hashimoto, R.; Hyde, T.M.; Herman, M.M.; Weinberger, D.R.; Kleinman, J.E. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch. Gen. Psychiatry, 2004, 61, 544-555.
48. Cotman, C.W.; Monaghan, D.T. Chemistry and anatomy of excitatory amino acid systems. In: Psychopharmacology: The Third Generation of Progress, Meltzer, H.Y., Ed., 1987, 197-210.
49. Kandel, E.R.; Siegelbaum, S.A. Synaptic Integration. In: Kandel, E.R., Schwartz, J.H., Jessel, T.M., Eds.; Principles of Neural Science, 2000, 207-228.
50. Kerwin, R.; Patel, S.; Meldrum, B. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience, 1990, 39, 25-32.
51. Bozkurt, A.; Zilles, K.; Schleicher, A.; Kamper, L.; Arigita, E.S.; Uylings, H.B.; Kötter, R. Distributions of transmitter receptors in the macaque cingulate cortex. Neuroimage, 2005, 25, 219-229.
52. Talbot, K.; Eidem, W.L.; Tinsley, C.L.; Benson, M.A.; Thompson, E.W.; Smith, R.J.; Hahn, C.G.; Siegel, S.J.; Trojanowski, J.Q.; Gur, R.E.; Blake, D.J.; Arnold, S.E. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J. Clin. Invest., 2004, 113, 1353-1363.
53. Weickert, C.S.; Rothmond, D.A.; Hyde, T.M.; Kleinman, J.E.; Straub, R.E. Reduced DTNBP1 (dysbindin-1) mRNA in the hippocampal formation of schizophrenia patients. Schizophr. Res., 2008, 98, 105-110.
54. Mao, J.; Mareci, T.; Scott, K.; Andrew, E. Selective inversion radiofrequency pulses by optimal control. J. Magn. Reson., 1986, 70, 310-318.
55. Elster, C.; Schubert, F.; Link, A.; Walzel, M.; Seifert, F.; Rinneberg, H. Quantitative magnetic resonance spectroscopy: semiparametric modeling and determination of uncertainties. Magn. Reson. Med., 2005, 53, 1288-1296.
56. Ashburner, J.; Friston, K. Multimodal image coregistration and partitioning--a unified framework. Neuroimage, 1997, 6, 209-217.
57. Livak, K.J. Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet. Anal., 1999, 14, 143-149.
58. International HapMap Consortium; Frazer, K.A.; Ballinger, D.G.; Cox, D.R.; et al. A second generation human haplotype map of over 3.1 million SNPs. Nature, 2007, 449, 851-861.
59. Kumamoto, N.; Matsuzaki, S.; Inoue, K.; Hattori, T.; Shimizu, S.; Hashimoto, R.; Yamatodani, A.; Katayama, T.; Tohyama, M. Hyperactivation of midbrain dopaminergic system in schizophrenia could be attributed to the down-regulation of dysbindin. Biochem. Biophys Res. Commun., 2006, 345, 904-909.
60. Hikita, T.; Taya, S.; Fujino, Y.; Taneichi-Kuroda, S.; Ohta, K.; Tsuboi, D.; Shinoda, T.; Kuroda, K.; Funahashi, Y.; Uraguchi-Asaki, J.; Hashimoto, R.; Kaibuchi, K. Proteomic analysis reveals novel binding partners of dysbindin, a schizophrenia-related protein. J. Neurochem., 2009, 110(5), 1567-1574.
61. Taneichi-Kuroda, S.; Taya, S.; Hikita, T.; Fujino, Y.; Kaibuchi, K. Direct interaction of Dysbindin with the AP-3 complex via its mu subunit. Neurochem. Int., 2009, 54, 431-438.
62. Goff, D.C.; Coyle, J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry, 2001, 158, 1367-1377.
63. Kim, J.S.; Kornhuber, H.H.; Schmid-Burgk, W.; Holzmuller, B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett., 1980, 20, 379-382
64. Nanitsos, E.K.; Nguyen, K.T.; St'astny, F.; Balcar, V.J. Glutamatergic hypothesis of schizophrenia: involvement of Na+/K+-dependent glutamate transport. J. Biomed. Sci., 2005, 12, 975-984.
65. Purdon, S.E.; Valiakalayil, A.; Hanstock, C.C.; Seres, P.; Tibbo, P. Elevated 3T proton MRS glutamate levels associated with poor Continuous Performance Test (CPT-0X) scores and genetic risk for schizophrenia. Schizophr. Res., 2008, 99, 218-224.
66. Burdick, K.E.; Lencz, T.; Funke, B.; Finn, C.T.; Szeszko, P.R.; Kane, J.M.; Kucherlapati, R.; Malhotra, A.K. Genetic variation in DTNBP1 influences general cognitive ability. Hum. Mol. Genet., 2006, 15, 1563-1568.
67. DeRosse, P.; Funke, B.; Burdick, K.E.; Lencz, T.; Ekholm, J.M.; Kane, J.M.; Kucherlapati, R.; Malhotra, A.K. Dysbindin genotype and negative symptoms in schizophrenia. Am. J. Psychiatry, 2006, 163, 532-534.
68. Fanous, A.H.; van den Oord, E.J.; Riley, B.P.; Aggen, S.H.; Neale, M.C.; O'Neill, F.A.; Walsh, D.; Kendler, K.S. Relationship between a high-risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia. Am. J. Psychiatry, 2005, 162, 1824-1832.
69. Elvevag, B.; Goldberg, T.E. Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol., 2000, 14, 1-21.
70. Newcomer, J.W.; Farber, N.B.; Jevtovic-Todorovic, V.; Selke, G.; Melson, A.K.; Hershey, T.; Craft, S.; Olney, J.W. Ketamineinduced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology, 1999, 20, 106-118.
71. Cherlyn, S.Y.; Woon, P.S.; Liu, J.J.; Ong, W.Y.; Tsai, G.C.; Sim, K. Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance. Neurosci. Biobehav. Rev., 2010, 34, 958-977.
72. Chaki, S. Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia. Eur. J. Pharmacol., 2010, 639, 59-66.
73. Tuominen, H.J.; Tiihonen, J.; Wahlbeck, K. Glutamatergic drugs for schizophrenia. Cochrane Database Syst. Rev., 2006, CD003730.
74. Li, S.J.; Wang, Y.; Pankiewicz, J.; Stein, E.A. Neurochemical adaptation to cocaine abuse: reduction of N-acetyl aspartate in thalamus of human cocaine abusers. Biol. Psychiatry, 1999, 45, 1481-1487.
75. Sailasuta, N.; Ernst, T.; Chang, L. Regional variations and the effects of age and gender on glutamate concentrations in the human brain. Magn. Reson. Imaging, 2008, 26, 667-675.
76. Chang, L.; Jiang, C.S.; Ernst, T. Effects of age and sex on brain glutamate and other metabolites. Magn. Reson. Imaging, 2009, 27, 142-145.
77. Haghighat, N. Estrogen (17beta-estradiol) enhances glutamine synthetase activity in C6-glioma cells. Neurochem. Res., 2005, 30, 661-667.
78. Charles, H.C.; Lazeyras, F.; Krishnan, K.R.; Boyko, O.B.; Patterson, L.J.; Doraiswamy, P.M.; McDonald, W.M. Proton spectroscopy of human brain: effects of age and sex. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2004, 18, 995-1004.
79. Schuff, N.; Ezekiel, F.; Gamst, A.C.; Amend, D.L.; Capizzano, A.A.; Maudsley, A.A.; Weiner, M.W. Region and tissue differences of metabolites in normally aged brain using multislice 1H magnetic resonance spectroscopic imaging. Magn. Reson. Med., 2001, 45, 899-907.
80. Segovia, G.; Porras, A.; del Arco, A.; Mora, F. Glutamatergic neurotransmission in aging: a critical perspective. Mech. Ageing Dev., 2001, 122, 1-29.
81. Kaiser, L.G.; Schuff, N.; Cashdollar, N.; Weiner, M.W. Agerelated glutamate and glutamine concentration changes in normal human brain: 1H MR spectroscopy study at 4 T. Neurobiol. Aging, 2005, 26, 665-672.
82. Ottersen, O.P.; Zhang, N.; Walberg, F. Metabolic compartmentation of glutamate and glutamine: morphological evidence obtained by quantitative immunocytochemistry in rat cerebellum. Neuroscience, 1992, 46, 519-534.
83. Patel, A.J.; Hunt, A.; Gordon, R.D.; Balazs, R. The activities in different neural cell types of certain enzymes associated with the metabolic compartmentation glutamate. Brain Res., 1982, 256, 3-11.
84. Li, D.; He, L. Association study between the dystrobrevin binding protein 1 gene (DTNBP1) and schizophrenia: a meta-analysis. Schizophr. Res., 2007, 96, 112-118.
85. Duan, J.; Martinez, M.; Sanders, A.R.; Hou, C.; Burrell, G.J.; Krasner, A.J.; Schwartz, D.B.; Gejman, P.V. DTNBP1 (Dystrobrevin binding protein 1) and schizophrenia: association evidence in the 3' end of the gene. Hum. Hered., 2007, 64, 97-106.